IDEAYA’s IDE849 Advances Toward Phase 3 in Lung Cancer
South San Francisco, California, August 31, 2026 IDEAYA Biosciences, Inc. announced the successful completion of a U.S. Food and...
antibody drug conjugate
Advertisement
Natera and Angiex Partner to Track AGX101 Response
Austin, Texas – August 27, 2026 Natera and Angiex have entered a new collaboration to assess treatment response to...
Daiichi Sankyo Begins Phase 1 Trial of CD25 ADC DS1025
Tokyo, Japan – August 27, 2026 Daiichi Sankyo has entered a new phase of oncology development with the first...
SOTIO’s SOT106 ADC Gets FDA Fast Track for Sarcoma
PRAGUE, Basel & Boston, Aug. 26, 2026 SOTIO Biotech announced that the U.S. Food and Drug Administration (FDA) has...
AbbVie Highlights Lung Cancer Pipeline Data at WCLC 2026
North Chicago, Illinois, USA, August 21, 2026 AbbVie has announced new clinical, translational and real-world research findings that will...
Advertisements
BioNTech Advances Lung Cancer Pipeline Ahead of WCLC 2026
MAINZ, Germany, August 20, 2026 BioNTech SE is set to highlight major progress across its lung cancer clinical development...
Daiichi Sankyo and AstraZeneca Report Enhertu Phase 3 Win
Tokyo, Japan — August 17, 2026 Daiichi Sankyo and AstraZeneca announced positive topline results from the DESTINY-Lung04 Phase 3...
Zai Lab Receives FDA Orphan Drug Designation for Zoci
SHANGHAI & CAMBRIDGE, Mass., Aug. 3, 2026 Zai Lab Limited announced that the U.S. Food and Drug Administration (FDA)...
Adlai Nortye Receives HREC Approval for AN4035 Phase I Trial
SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 3, 2026 Adlai Nortye Ltd. has advanced its oncology pipeline after submitting a...
IMPACT Therapeutics Names IMP3201 First Dual-Payload ADC Candidate
SHANGHAI, China, July 27, 2026 IMPACT Therapeutics announced the nomination of IMP3201 as a preclinical candidate (PCC), marking the...
Advertisement
